PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015

Aaron Gerds, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic discusses the PERSIST-1 Phase III Study Results of Pacritinib from ASH 2015